RxDoctor Payments Data

Jessica Shepley

Psychiatric/Mental Health · West Palm Beach, FLNPI 1700400140

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (47.7%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Janssen Scientific Affairs, LLC at 48.9% of the total. Reporting peaked in 2023 at $7,769 and has fallen 88.4% since, to $902 in 2025. Among psychiatric/mental health clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,159in general payments, 2019–2025

Across 97 payments — averaging $145.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Scientific Affairs, LLC$7K
  • Johnson & Johnson$5K
  • AbbVie$368
  • Teva Pharmaceuticals USA, Inc.$324
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$268
  • Axsome Therapeutics, Inc.$252
  • plus $577 from 9 others

What the payments were for

  • Consulting fees$6,75048%
  • Speaking & faculty fees$3,75026%
  • Travel & lodging$7695%
  • Food & beverage$2,89020%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,159 in reported general payments places this provider in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$133,514
Medicare patients
17
Services billed
1,068

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl115$205,519

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$5,444$205,519115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in West Palm Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →